Literature DB >> 25240918

Development and validation of a prognostic index for fracture risk in older men undergoing prostate cancer treatment.

Tisheeka R Graham-Steed1, Pamela R Soulos1, Natalie Dearing2, John Concato3, Mary E Tinetti4, Cary P Gross5.   

Abstract

OBJECTIVES: Men treated with androgen deprivation therapy (ADT) or radiation therapy (RT) for prostate cancer have an increased risk for fractures. Given uncertainty as to whether specific clinical factors can identify men at increased risk, we sought to develop a prognostic index for risk of fracture in this population.
MATERIALS AND METHODS: We used the Surveillance, Epidemiology, and End Results-Medicare database to identify men who received ADT or RT after being diagnosed with localized prostate cancer in 2007-2009. Cox proportional hazards models tested the association of potential risk factors with fracture. In a derivation group, hazard ratios were used to assign points for factors independently related to fracture. The prognostic index was then applied to a validation group.
RESULTS: The sample of 5824 men had a median age of 73.0 years; 82.9% were white and 8.6% had a fracture within 2 years of treatment for prostate cancer. The Cox model identified 8 variables (age, race, hormone treatment, Elixhauser score, anxiety, Parkinson's, fall-inducing medications and disability status) independently associated with fracture. In the derivation cohort, 4.3% of the sample experienced a fracture in the low-risk group, 8.9% in the intermediate group, and 19.2% in the high-risk group (C statistic, 0.749). The index was applied to the validation cohort (C statistic, 0.782).
CONCLUSION: The prognostic index can help to identify patients at increased risk for fracture. This underscores the importance of identifying risk factors for fracture, given the substantial variation in fracture risk in men treated with ADT or RT.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Androgen deprivation therapy; Fractures; Prostate cancer; Radiation therapy; Risk score

Mesh:

Substances:

Year:  2014        PMID: 25240918      PMCID: PMC4252659          DOI: 10.1016/j.jgo.2014.08.004

Source DB:  PubMed          Journal:  J Geriatr Oncol        ISSN: 1879-4068            Impact factor:   3.599


  57 in total

Review 1.  Bone loss and fracture risk associated with cancer therapy.

Authors:  Theresa A Guise
Journal:  Oncologist       Date:  2006 Nov-Dec

2.  The acute medical care costs of fall-related injuries among the U.S. older adults.

Authors:  Bahman S Roudsari; Beth E Ebel; Phaedra S Corso; Noelle-Angelique M Molinari; Thomas D Koepsell
Journal:  Injury       Date:  2005-11       Impact factor: 2.586

3.  Physician practices of bone density testing and drug prescribing to prevent or treat osteoporosis during androgen deprivation therapy.

Authors:  Tawee Tanvetyanon
Journal:  Cancer       Date:  2005-01-15       Impact factor: 6.860

Review 4.  Androgen deprivation therapy for prostate cancer.

Authors:  Nima Sharifi; James L Gulley; William L Dahut
Journal:  JAMA       Date:  2005-07-13       Impact factor: 56.272

Review 5.  Androgen deprivation therapy: monitoring and managing the complications.

Authors:  Celestia Higano
Journal:  Hematol Oncol Clin North Am       Date:  2006-08       Impact factor: 3.722

6.  Prevention and management of osteoporosis in men receiving androgen deprivation therapy: a survey of urologists and radiation oncologists.

Authors:  Shabbir M H Alibhai; Sameera Rahman; Padraig R Warde; Michael A S Jewett; Taha Jaffer; Angela M Cheung
Journal:  Urology       Date:  2006-07       Impact factor: 2.649

7.  Risk of fracture after androgen deprivation for prostate cancer.

Authors:  Vahakn B Shahinian; Yong-Fang Kuo; Jean L Freeman; James S Goodwin
Journal:  N Engl J Med       Date:  2005-01-13       Impact factor: 91.245

8.  The geographic incidence and treatment variation of common fractures of elderly patients.

Authors:  Scott M Sporer; James N Weinstein; Kenneth J Koval
Journal:  J Am Acad Orthop Surg       Date:  2006-04       Impact factor: 3.020

Review 9.  Multidisciplinary approach to the geriatric oncology patient.

Authors:  Catherine Terret; Gilbert B Zulian; Arash Naiem; Gilles Albrand
Journal:  J Clin Oncol       Date:  2007-05-10       Impact factor: 44.544

Review 10.  Skeletal morbidity in men with prostate cancer: quality-of-life considerations throughout the continuum of care.

Authors:  Fred Saad; Carl Olsson; Claude C Schulman
Journal:  Eur Urol       Date:  2004-12       Impact factor: 20.096

View more
  2 in total

1.  Efficacy and safety of darolutamide in Japanese patients with nonmetastatic castration-resistant prostate cancer: a sub-group analysis of the phase III ARAMIS trial.

Authors:  Hiroji Uemura; Hisashi Matsushima; Kazuki Kobayashi; Hiroya Mizusawa; Hiroaki Nishimatsu; Karim Fizazi; Matthew Smith; Neal Shore; Teuvo Tammela; Ken-Ichi Tabata; Nobuaki Matsubara; Masahiro Iinuma; Hirotsugu Uemura; Mototsugu Oya; Tetsuo Momma; Mutsushi Kawakita; Satoshi Fukasawa; Tadahiro Kobayashi; Iris Kuss; Marie-Aude Le Berre; Amir Snapir; Toni Sarapohja; Kazuhiro Suzuki
Journal:  Int J Clin Oncol       Date:  2020-11-23       Impact factor: 3.402

Review 2.  Managing an Older Adult with Cancer: Considerations for Radiation Oncologists.

Authors:  Sanders Chang; Nathan E Goldstein; Kavita V Dharmarajan
Journal:  Biomed Res Int       Date:  2017-12-13       Impact factor: 3.411

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.